US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Seaport Therapeutics

22.30

+0.55002.53%

Volume:46.56K

Turnover:1.03M

Market Cap:1.19B

PE:-8.86

High:22.75

Open:21.58

Low:21.58

Close:21.75

52wk High:28.38

52wk Low:14.85

Shares:53.53M

Float Shares:14.16M

Volume Ratio:0.71

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5160

EPS(LYR):-10.0430

ROE:-28.08%

ROA:-18.90%

PB:2.82

PE(LYR):-2.22

Loading ...

Overview Company News Filings

Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo

PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5

THOMSON REUTERS

PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported

THOMSON REUTERS

PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA

THOMSON REUTERS

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live

Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint

Seaport Therapeutics Says Phase 1 Trial Shows GlyphAllo 375 Mg Does not Impair Next-Morning Driving vs Placebo

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of Glyphallo™ in Healthy Volunteers

THOMSON REUTERS

Seaport Therapeutics - Key Secondary Endpoint Met for 250 Mg Glyphallo on Day 2

THOMSON REUTERS

Seaport Therapeutics - Enrolling Buoy-1 Phase 2B Trial for Glyphallo; Topline Data Expected First Half 2027

THOMSON REUTERS

Seaport Therapeutics - Glyphallo Well-Tolerated with no Serious Adverse Events Reported

THOMSON REUTERS

Seaport Therapeutics - Phase 1 Trial Meets Primary Endpoint for 375 Mg Glyphallo on Day 5

THOMSON REUTERS

Seaport Therapeutics Participates in Citi Biopharma Back to School Conference Fireside Chat

Seaport Therapeutics Initiated at Buy by Jones Trading

JonesTrading Initiates Coverage on Seaport Therapeutics With Buy Rating, $32 Price Target

MT Newswires Live

Wall Street Analysts Are Bullish on Top NA Picks

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/SPTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","market":"US","secType":"STK","nameCN":"Seaport Therapeutics","latestPrice":22.3,"timestamp":1789056518353,"preClose":21.75,"halted":0,"volume":46556,"delay":0,"changeRate":0.025287356321839115,"floatShares":14160000,"shares":53530550,"eps":-2.516,"marketStatus":"Trading","change":0.55,"latestTime":"09-10 12:08:45 EDT","open":21.58,"high":22.75,"low":21.58,"amount":1032558.5406000001,"amplitude":0.053793,"askPrice":22.61,"askSize":125,"bidPrice":22.15,"bidSize":41,"shortable":3,"etf":0,"ttmEps":-2.516,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":21.75,"postHourTrading":{"tag":"盘后","latestPrice":21.75,"preClose":21.75,"latestTime":"19:30 EDT","volume":1215,"amount":26426.25,"timestamp":1788996608005,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.708861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","floatShares":14160000,"roa":"-18.90%","roe":"-28.08%","lyrEps":-10.043037,"volumeRatio":0.708861,"shares":53530550,"dividePrice":0,"high":22.75,"amplitude":0.053793,"preClose":21.75,"low":21.58,"week52Low":14.85,"pbRate":"2.82","week52High":28.3833,"institutionHeld":0,"latestPrice":22.3,"committee":-0.506024,"eps":-2.516,"divideRate":0,"volume":46556,"delay":0,"ttmEps":-2.516,"open":21.58,"prevYearClose":18,"prevWeekClose":24.86,"prevMonthClose":23.68,"prevQuarterClose":21.72,"fiveDayClose":24.91,"twentyDayClose":23.8,"sixtyDayClose":17.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-03","symbol":"SPTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785729600000,"reportTimeType":"pre","actualEps":-1.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.4286,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":7,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPTX","date":"2026-09-08","current":-8.644674,"percent":0.813953,"low":-14.505892,"twenty":-12.776644,"median":-11.99625,"eighty":-10.006847,"high":-9.149163,"avg":-11.709063,"sd":1.352664,"marketCap":1330769473},"quantilePoints":[{"date":"2026-05-08","current":-10.976498,"twenty":-12.440976,"median":-11.330579,"eighty":-11.259763,"marketCap":821931163},{"date":"2026-05-15","current":-11.99625,"twenty":-12.004748,"median":-11.348283,"eighty":-11.231436,"marketCap":898291219},{"date":"2026-05-22","current":-12.173291,"twenty":-12.004748,"median":-11.330579,"eighty":-11.135126,"marketCap":911548174},{"date":"2026-05-29","current":-13.31343,"twenty":-12.537286,"median":-11.684659,"eighty":-11.163453,"marketCap":996922959},{"date":"2026-06-05","current":-12.661922,"twenty":-12.698746,"median":-12.017495,"eighty":-11.247016,"marketCap":948137367},{"date":"2026-06-12","current":-12.548616,"twenty":-12.593938,"median":-12.03874,"eighty":-11.316416,"marketCap":939652917},{"date":"2026-06-18","current":-10.501726,"twenty":-12.6166,"median":-12.03874,"eighty":-11.222938,"marketCap":915372405},{"date":"2026-06-26","current":-11.889673,"twenty":-12.53162,"median":-11.895161,"eighty":-11.165224,"marketCap":1036351448},{"date":"2026-07-02","current":-13.173217,"twenty":-12.752567,"median":-12.017495,"eighty":-11.198861,"marketCap":1148230297},{"date":"2026-07-10","current":-12.595929,"twenty":-12.752567,"median":-12.03874,"eighty":-11.215593,"marketCap":1097911580},{"date":"2026-07-17","current":-11.987935,"twenty":-12.752567,"median":-12.12726,"eighty":-11.302253,"marketCap":1044916336},{"date":"2026-07-24","current":-13.474144,"twenty":-12.866109,"median":-12.187454,"eighty":-11.330579,"marketCap":1174460267},{"date":"2026-07-31","current":-12.479243,"twenty":-12.804736,"median":-12.201617,"eighty":-11.330579,"marketCap":1087740776},{"date":"2026-08-07","current":-14.1804,"twenty":-12.896856,"median":-12.347233,"eighty":-11.365987,"marketCap":1236020399},{"date":"2026-08-14","current":-9.423399,"twenty":-12.896856,"median":-12.221306,"eighty":-11.295171,"marketCap":1269209340},{"date":"2026-08-21","current":-9.552568,"twenty":-12.881452,"median":-12.180373,"eighty":-11.146457,"marketCap":1286606769},{"date":"2026-08-28","current":-10.432907,"twenty":-12.804736,"median":-12.123719,"eighty":-11.036024,"marketCap":1405176937},{"date":"2026-09-04","current":-9.653917,"twenty":-12.782309,"median":-12.017495,"eighty":-10.432907,"marketCap":1300257059},{"date":"2026-09-08","current":-9.88046,"twenty":-12.776644,"median":-11.99625,"eighty":-10.006847,"marketCap":1330769473}],"updateTime":1789028772155},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666631599","title":"Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666631599","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666631599?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:35","pubTimestamp":1789047319,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz maintained a Buy rating on Seaport Therapeutics, Inc. today and set a price target of $35.00. Nochomovitz covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-seaport-therapeutics-inc-sptx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-buy-rating-on-seaport-therapeutics-inc-sptx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567255","title":"Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567255","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567255?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:53","pubTimestamp":1789037580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666953424","title":"PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666953424","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666953424?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:18","pubTimestamp":1788974333,"startTime":"0","endTime":"0","summary":"BRIEF-PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAlloSept 9 (Reuters)-PureTech Health PLCPRTC.L:PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS REPORTS POS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PRTC.UK","SPTX","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534453","title":"PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534453?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","PRTC.UK","BK4007","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534285","title":"PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534285?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PRTC.UK","BK5083","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666498534","title":"PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2666498534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666498534?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:14","pubTimestamp":1788974040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA62HR5N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK5083","BK4007","PRTC.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666351825","title":"Sector Update: Healthcare Stocks Mixed Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666351825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666351825?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:16","pubTimestamp":1788959818,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.3%.InnovAge Holding  shares were up more than 10% after the company reported that it swung to earnings in fiscal Q4 amid stronger-than-expected sales growth.Seaport Therapeutics  stock was nearly 4% higher after the company said its phase 1 driving simulation trial of GlyphAllo met its primary endpoint, with the 375 mg dose showing no next-morning driving impairment versus placebo after multiple-day dosing.Evommune's  phase 2b trial of EVO756 to treat adults with moderate-to-severe atopic dermatitis didn't meet its primary and secondary endpoints in any of the doses studied, the company said. Evommune shares were down more than 8% pre-bell.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","INNV","BK4007","EVMN","LU0029874061.USD","LU0128526141.USD","SPTX","BK4139","BK4585","XLV","BK4196","IBB","XBI","BK4137","HCSG","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751587","title":"Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751587","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952216,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics (SPTX) announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, a novel, Glyphed oral prodru...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-announces-phase-1-trial-of-glyphallo-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-announces-phase-1-trial-of-glyphallo-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587398","title":"Seaport Therapeutics Says Phase 1 Trial Shows GlyphAllo 375 Mg Does not Impair Next-Morning Driving vs Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587398?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951732,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics says Phase 1 trial shows GlyphAllo 375 mg does not impair next-morning driving vs placeboSeaport Therapeutics reported positive topline Phase 1 driving simulator results for Glyph","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbv5Xwz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958209","title":"Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of Glyphallo™ in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958209?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8RSHWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666820145","title":"Seaport Therapeutics - Key Secondary Endpoint Met for 250 Mg Glyphallo on Day 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2666820145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666820145?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8RSHWH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666758204","title":"Seaport Therapeutics - Enrolling Buoy-1 Phase 2B Trial for Glyphallo; Topline Data Expected First Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666758204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666758204?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8RSHWH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582068","title":"Seaport Therapeutics - Glyphallo Well-Tolerated with no Serious Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582068?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8RSHWH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582031","title":"Seaport Therapeutics - Phase 1 Trial Meets Primary Endpoint for 375 Mg Glyphallo on Day 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582031?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8RSHWH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663707072","title":"Seaport Therapeutics Participates in Citi Biopharma Back to School Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2663707072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663707072?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174053,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics participates in Citi Biopharma Back to School conference fireside chatSeaport Therapeutics will attend the 21st Annual Wells Fargo Healthcare Conference on September 8-10, 2026.Management will also join Citi’s 2026 Biopharma Back to School Conference on September 9-10, 2026.A fireside chat is scheduled for September 9, 2026 at 1:00 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on August 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL9KvgrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","LU0106831901.USD","LU1668664300.SGD","LU1791807156.HKD","LU0072461881.USD","TFNS","LU1506573853.SGD","IE00BSNM7G36.USD","BK4504","LU2456880835.USD","LU0320765646.SGD","LU0170899867.USD","LU0128525689.USD","LU0162691827.USD","BK4585","LU2462157665.USD","LU0310800965.SGD","LU0130102774.USD","LU1366192091.USD","LU2125154935.USD","BK4559","LU2417539215.USD","LU0203347892.USD","IYF","LU1074936037.SGD","BK4534","LU1244550221.USD","LU1244550577.SGD","LU0098860793.USD","LU0052756011.USD","LU2236285917.USD","LU1267930227.SGD","BK4588","LU0980610538.SGD","LU0130517989.USD","LU1244550494.USD","LU0314106906.USD","BK4007","LU0203345920.USD","LU0648001328.SGD","SPTX","LU2360032135.SGD","LU1162221912.USD","LU1201861249.SGD","LU0477156953.USD","FTXO","LU2125154778.USD","LU1144417596.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662743838","title":"Seaport Therapeutics Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2662743838","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662743838?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:26","pubTimestamp":1787757960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662158457","title":"JonesTrading Initiates Coverage on Seaport Therapeutics With Buy Rating, $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662158457","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662158457?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:22","pubTimestamp":1787743339,"startTime":"0","endTime":"0","summary":"JonesTrading Initiates Coverage on Seaport Therapeutics With Buy Rating, $32 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662529997","title":"Wall Street Analysts Are Bullish on Top NA Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2662529997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662529997?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:30","pubTimestamp":1787689822,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Seaport Therapeutics, Inc. (SPTX) and PicS N.V. Class A (PIC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-24?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-24?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OWNB","BLSH","BK4007","SPTX","BLSX","BK4112","BLSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660834682","title":"Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660834682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660834682?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:17","pubTimestamp":1787221020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373765","title":"Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373765?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:36","pubTimestamp":1785839760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPTX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}